These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 17922877)

  • 1. TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2.
    Natoni A; MacFarlane M; Inoue S; Walewska R; Majid A; Knee D; Stover DR; Dyer MJ; Cohen GM
    Br J Haematol; 2007 Nov; 139(4):568-77. PubMed ID: 17922877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1.
    MacFarlane M; Inoue S; Kohlhaas SL; Majid A; Harper N; Kennedy DB; Dyer MJ; Cohen GM
    Cell Death Differ; 2005 Jul; 12(7):773-82. PubMed ID: 15861184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors.
    Stadel D; Mohr A; Ref C; MacFarlane M; Zhou S; Humphreys R; Bachem M; Cohen G; Möller P; Zwacka RM; Debatin KM; Fulda S
    Clin Cancer Res; 2010 Dec; 16(23):5734-49. PubMed ID: 20940278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death.
    Georgakis GV; Li Y; Humphreys R; Andreeff M; O'Brien S; Younes M; Carbone A; Albert V; Younes A
    Br J Haematol; 2005 Aug; 130(4):501-10. PubMed ID: 16098063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies.
    MacFarlane M; Kohlhaas SL; Sutcliffe MJ; Dyer MJ; Cohen GM
    Cancer Res; 2005 Dec; 65(24):11265-70. PubMed ID: 16357130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) induces apoptosis in primary renal cell carcinoma cells in vitro and inhibits tumor growth in vivo.
    Zeng Y; Wu XX; Fiscella M; Shimada O; Humphreys R; Albert V; Kakehi Y
    Int J Oncol; 2006 Feb; 28(2):421-30. PubMed ID: 16391797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels.
    Nawrocki ST; Carew JS; Douglas L; Cleveland JL; Humphreys R; Houghton JA
    Cancer Res; 2007 Jul; 67(14):6987-94. PubMed ID: 17638911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo.
    Pukac L; Kanakaraj P; Humphreys R; Alderson R; Bloom M; Sung C; Riccobene T; Johnson R; Fiscella M; Mahoney A; Carrell J; Boyd E; Yao XT; Zhang L; Zhong L; von Kerczek A; Shepard L; Vaughan T; Edwards B; Dobson C; Salcedo T; Albert V
    Br J Cancer; 2005 Apr; 92(8):1430-41. PubMed ID: 15846298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation.
    Mühlenbeck F; Schneider P; Bodmer JL; Schwenzer R; Hauser A; Schubert G; Scheurich P; Moosmayer D; Tschopp J; Wajant H
    J Biol Chem; 2000 Oct; 275(41):32208-13. PubMed ID: 10807904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells.
    Bremer E; de Bruyn M; Samplonius DF; Bijma T; ten Cate B; de Leij LF; Helfrich W
    J Mol Med (Berl); 2008 Aug; 86(8):909-24. PubMed ID: 18504532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma.
    Younes M; Georgakis GV; Rahmani M; Beer D; Younes A
    Eur J Cancer; 2006 Mar; 42(4):542-7. PubMed ID: 16426839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D.
    Olsson A; Diaz T; Aguilar-Santelises M; Osterborg A; Celsing F; Jondal M; Osorio LM
    Leukemia; 2001 Dec; 15(12):1868-77. PubMed ID: 11753607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin.
    Belyanskaya LL; Marti TM; Hopkins-Donaldson S; Kurtz S; Felley-Bosco E; Stahel RA
    Mol Cancer; 2007 Oct; 6():66. PubMed ID: 17953743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies.
    Inoue S; MacFarlane M; Harper N; Wheat LM; Dyer MJ; Cohen GM
    Cell Death Differ; 2004 Dec; 11 Suppl 2():S193-206. PubMed ID: 15608694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis.
    Inoue S; Harper N; Walewska R; Dyer MJ; Cohen GM
    Mol Cancer Ther; 2009 Nov; 8(11):3088-97. PubMed ID: 19887558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo.
    Marini P; Denzinger S; Schiller D; Kauder S; Welz S; Humphreys R; Daniel PT; Jendrossek V; Budach W; Belka C
    Oncogene; 2006 Aug; 25(37):5145-54. PubMed ID: 16636678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesis.
    Secchiero P; Zauli G
    Curr Opin Hematol; 2008 Jan; 15(1):42-8. PubMed ID: 18043245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced metastasis suppression by targeting TRAIL receptor 2 in a murine model of triple-negative breast cancer.
    Malin D; Chen F; Schiller C; Koblinski J; Cryns VL
    Clin Cancer Res; 2011 Aug; 17(15):5005-15. PubMed ID: 21653692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia.
    MacFarlane M; Harper N; Snowden RT; Dyer MJ; Barnett GA; Pringle JH; Cohen GM
    Oncogene; 2002 Oct; 21(44):6809-18. PubMed ID: 12360407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TRAIL receptor signalling and modulation: Are we on the right TRAIL?
    Mahalingam D; Szegezdi E; Keane M; de Jong S; Samali A
    Cancer Treat Rev; 2009 May; 35(3):280-8. PubMed ID: 19117685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.